Navigation Links
Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
Date:12/4/2007

ROCKVILLE, Md., Dec. 4 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that it has completed the sale of assets constituting its Biologics strategic business unit (SBU) to Biotest Pharmaceuticals Corporation, a wholly-owned subsidiary of Biotest AG, for $185 million in cash. Subject to the interim arrangements described below, Biotest has acquired or will acquire the Biologics SBU's products, including Nabi- HB(R) and other plasma business assets, including Nabi's state-of-the-art plasma protein production plant and nine FDA-certified plasma collection centers across the U.S. The acquisition also includes certain of Nabi's Corporate Shared Services group assets, the company's Boca Raton, Florida headquarters and other facilities as well as the assumption of certain liabilities.

Nabi Biopharmaceuticals is now headquartered in Rockville, Maryland.

Nabi will retain, on an interim basis pending Biotest's receipt of certain Florida regulatory approvals and licenses, title to all Nabi-HB(R) inventory and work-in-progress, and regulatory oversight and operational authority for the manufacture, marketing, distribution and sale of Nabi-HB(R). Upon receipt of such regulatory approvals, title to Nabi-HB(R) inventory and work-in- progress, and oversight and authority for the manufacture, marketing, distribution and sale of Nabi-HB(R) will transfer to Biotest. During the interim period prior to receipt of such approvals, revenues and expenses relating to Nabi-HB(R) sales shall be attributed to Biotest and Biotest shall indemnify Nabi for liability arising from post-closing conduct of the Biologics SBU.

"The completion of this transaction marks a significant milestone in our strategic alternatives process. Nabi is now focused on building and realizing the significant value of Nabi's remaining assets including NicVax, our proprietary smoking cessation vaccine for treatment of nicotine addiction and prevention of smoking relapse, StaphVax, and our cash and PhosLo milestone and royalty opportunities," said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of gram positive bacterial infections and nicotine addiction. Nabi Biopharmaceuticals is currently developing NicVAX, an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and StaphVAX, a vaccine designed to prevent the most dangerous and prevalent strains of S. aureus bacterial infections. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.

Forward-Looking Statements

Statements in this release that are not strictly historical are forward- looking statements including statements about our strategic alternatives process and clinical trials and studies. You can identify these forward- looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our strategic alternatives process and our ability to: successfully partner with third parties to fund, develop, and manufacture our pipeline products, including NicVAX and our gram-positive infections products; obtain successful clinical trial results; realize anticipated cost savings related to job elimination due to greater than anticipated severance-related costs or other factors; maintain a sufficient cash balance and generate sufficient cash flow from milestone or royalty payments to fund our development and commercialization activities; attract and maintain the human and financial resources to bring to market products in development; depend upon third parties to manufacture or fill our products; achieve approval and market acceptance of our products; enter into and maintain arrangements with third parties to market and sell our products; manufacture NicVAX or other products; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter ended September 29, 2007 filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
3. Eligard(R) six-month formulation successfully completes European approval procedure
4. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
7. GSI Securitization Completes Merger and Domicile Transfer
8. Medical Services International Inc. Completes Testing for European Union (EU) Application
9. Inverness Completes Acquisition of Cholestech
10. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
11. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Give To ... users to search for and donate to Give To Cure’s campaign that is crowdfunding ... that lets users make and share payments through a smart device. In 2015 alone, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
(Date:2/5/2016)... ... 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of ... Day to individuals in need. The event is scheduled to take place on February ... is to provide dental care to community members in need. Each patient will be ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
Breaking Medicine Technology: